Lakefront Biotherapeutics NV
GLPGF
$28.08
$0.000.00%
OTC PK
| 03/31/2026 | 12/31/2025 | 06/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -90.57% | 1,321.15% | -11.60% | -11.60% | 16.42% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -90.57% | 1,321.15% | -11.60% | -11.60% | 16.42% |
| Cost of Revenue | -80.15% | 12.44% | 16.92% | 16.92% | 156.82% |
| Gross Profit | 73.72% | 2,529.48% | -197.53% | -197.53% | -904.12% |
| SG&A Expenses | -11.60% | -4.92% | -2.40% | -2.40% | 37.90% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 82.10% | -131.03% | -21.27% | -21.27% | 31.92% |
| Total Operating Expenses | -67.25% | -6.84% | 11.13% | 11.13% | 137.05% |
| Operating Income | 56.23% | 1,604.41% | -57.49% | -57.49% | -364.36% |
| Income Before Tax | 109.73% | 4,236.05% | -2,792.15% | -2,792.15% | -760.91% |
| Income Tax Expenses | 104.21% | 1,945.95% | 104.80% | 104.80% | -209.60% |
| Earnings from Continuing Operations | 109.80% | 4,223.72% | -2,462.93% | -2,462.93% | -737.45% |
| Earnings from Discontinued Operations | -42.54% | -109.33% | -131.65% | -131.65% | -98.33% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 110.30% | 3,492.13% | -1,341.01% | -1,341.01% | -264.83% |
| EBIT | 56.23% | 1,604.41% | -57.49% | -57.49% | -364.36% |
| EBITDA | 59.74% | 2,192.31% | -40.46% | -40.46% | -433.54% |
| EPS Basic | 110.30% | 3,489.35% | -1,340.35% | -1,340.35% | -264.86% |
| Normalized Basic EPS | 109.73% | -- | -202.03% | -202.03% | -761.07% |
| EPS Diluted | 110.30% | 3,502.16% | -1,340.35% | -1,340.35% | -264.86% |
| Normalized Diluted EPS | 109.73% | -- | -203.35% | -203.35% | -761.07% |
| Average Basic Shares Outstanding | 0.05% | 0.01% | 0.02% | 0.02% | -0.02% |
| Average Diluted Shares Outstanding | 0.05% | -0.03% | -0.43% | -0.43% | -0.02% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |